Home Cart Sign in  
Chemical Structure| 1687736-54-4 Chemical Structure| 1687736-54-4

Structure of SGC707
CAS No.: 1687736-54-4

Chemical Structure| 1687736-54-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SGC707 is a chemical probe of PRMT3 with IC50 of 31 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SGC707

CAS No. :1687736-54-4
Formula : C16H18N4O2
M.W : 298.34
SMILES Code : O=C(NCC(N1CCCC1)=O)NC2=CC3=C(C=NC=C3)C=C2
MDL No. :MFCD28411624
InChI Key :DMIDPTCQPIJYFE-UHFFFAOYSA-N
Pubchem ID :90642938

Safety of SGC707

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of SGC707

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
GSC262 cells 10 µM Inhibited GSC cell growth Cell Death Dis. 2022 Nov 9;13(11):943.
A549 1.6 µM (EC50) Stabilized PRMT3 with EC50 of 1.6 μM Angew Chem Int Ed Engl. 2015 Apr 20;54(17):5166-70.
HEK293 1.3 µM (EC50) Stabilized PRMT3 with EC50 of 1.3 μM Angew Chem Int Ed Engl. 2015 Apr 20;54(17):5166-70.
GSC28 cells 10 µM Inhibited GSC cell growth Cell Death Dis. 2022 Nov 9;13(11):943.
U87 cells 10 µM Inhibited GBM cell growth Cell Death Dis. 2022 Nov 9;13(11):943.
U251 cells 10 µM Inhibited GBM cell growth Cell Death Dis. 2022 Nov 9;13(11):943.
HMO6 cells 10 µM No effect on normal brain cell growth Cell Death Dis. 2022 Nov 9;13(11):943.
MOLT4 cells 10 µM 24 hours Evaluate PRMT3 degradation effect, 11 significantly degraded PRMT3 protein Adv Sci (Weinh). 2024 Oct;11(38):e2405963.
MOLM13 cells 10 µM 24 hours Evaluate PRMT3 degradation effect, 11 significantly degraded PRMT3 protein Adv Sci (Weinh). 2024 Oct;11(38):e2405963.
MV-4-11 cells 10 µM 24 hours Evaluate PRMT3 degradation effect, 11 significantly degraded PRMT3 protein Adv Sci (Weinh). 2024 Oct;11(38):e2405963.
RS4;11 cells 10 µM 24 hours Evaluate PRMT3 degradation effect, 11 significantly degraded PRMT3 protein Adv Sci (Weinh). 2024 Oct;11(38):e2405963.
Huh7 cells 1 µM 48 hours Inhibited PRMT3-mediated LDHA methylation, reduced glucose consumption and lactate production Clin Transl Med. 2022 Jan;12(1):e686.
SNU398 cells 1 µM 48 hours Inhibited PRMT3-mediated LDHA methylation, reduced glucose consumption and lactate production Clin Transl Med. 2022 Jan;12(1):e686.
Human mesenchymal stem cells (hMSCs) 10 µM 96 hours SGC707 significantly inhibited the osteogenic differentiation ability of hMSCs, as evidenced by reduced ALP activity and calcium deposition. Cell Death Dis. 2019 Aug 5;10(8):581.
HEB cells 10 µM No effect on normal brain cell growth Cell Death Dis. 2022 Nov 9;13(11):943.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
LDL receptor knockout mice Atherogenic Western-type diet-fed model Intraperitoneal injection 0.3 mg per injection, approximately 10 mg/kg 3 times per week for 3 weeks To investigate the effect of SGC707 on hepatic steatosis and plasma triglyceride levels. Results showed that SGC707 treatment reduced liver triglyceride stores by 50% and plasma triglyceride levels by 32%, but induced pruritus and skin lesions. Sci Rep. 2022 Jan 10;12(1):483
NOG-dKO mice CDX and PDX models Intraperitoneal injection 10 mg/kg Every 2 days until the end of the study SGC707 combined with anti-PD-1 therapy showed more potent antitumor effects. Adv Sci (Weinh). 2023 Dec;10(36):e2303812
C57BL/6 mice Chronic kidney disease (CKD) model Intraperitoneal injection 10 mg/kg For 10 weeks To investigate the effect of SGC707 on vascular calcification in CKD mice. Results showed that SGC707 alleviated CKD-induced vascular calcification and renal injury. Mol Med. 2024 Jan 10;30(1):8
C57BL/6 mice T0901317 and palm oil-induced hepatic steatosis model Intraperitoneal injection 10 or 30 mg/kg Three injections over 4 days To evaluate the effect of PRMT3 inhibition on LXR-mediated hepatic lipogenesis. Results showed that SGC707 treatment significantly reduced hepatic lipogenic gene expression and liver triglyceride content. Br J Pharmacol. 2018 Aug;175(15):3175-3183
Mice Osteoporosis model Subcutaneous implantation of ALZET pump 20 mg/kg/day Continuous for 6 weeks SGC707 treatment resulted in bone loss in mice, characterized by reduced bone density and trabecular number. Cell Death Dis. 2019 Aug 5;10(8):581.
Nude mice GSC262 xenograft model Intraperitoneal injection 30 mg/kg Daily from day 21 to day 34 Inhibited tumor growth Cell Death Dis. 2022 Nov 9;13(11):943.
BALB/C nude mice Subcutaneous xenograft model Intraperitoneal injection 30 mg/kg Every 2 days for approximately 30 days SGC707 treatment significantly inhibited PRMT3 overexpression-induced tumor growth Clin Transl Med. 2022 Jan;12(1):e686.
Mice WT mice Intraperitoneal injection 30 mg/kg Single injection, 24 h before viral infection PRMT3 inhibitor (SGC707) treatment promotes antiviral innate immunity in vivo. Proc Natl Acad Sci U S A. 2023 Sep 5;120(36):e2214956120

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.35mL

0.67mL

0.34mL

16.76mL

3.35mL

1.68mL

33.52mL

6.70mL

3.35mL

References

 

Historical Records

Categories